A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Takeda
Alaunos Therapeutics
Tempus AI
Incyte Corporation
Actym Therapeutics, Inc.
Day One Biopharmaceuticals, Inc.
Ikena Oncology
Day One Biopharmaceuticals, Inc.
Alaunos Therapeutics
Mirati Therapeutics Inc.
Elevation Oncology
Merck Sharp & Dohme LLC
The Netherlands Cancer Institute
Mirati Therapeutics Inc.
ABM Therapeutics Corporation
Novartis
NantCell, Inc.
Maastricht University Medical Center
NantCell, Inc.
Pfizer
ADC Therapeutics S.A.
Ikena Oncology
Rutgers, The State University of New Jersey
pharmaand GmbH
Fate Therapeutics
Genmab
Montefiore Medical Center
MacroGenics
National Institutes of Health Clinical Center (CC)
Lumos Pharma
Cambridge University Hospitals NHS Foundation Trust
Tocagen Inc.
National Institutes of Health Clinical Center (CC)
CureOne
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
Western Regional Medical Center
Western Regional Medical Center
Masonic Cancer Center, University of Minnesota
New York State Psychiatric Institute
Par Pharmaceutical, Inc.
Amgen
Calando Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Auron Healthcare GmbH
National Cancer Institute (NCI)
Stanford University
Massachusetts General Hospital
Cancer Research UK